Philippines - English - FDA (Food And Drug Administration)

dr. zen's research, inc. - cliostazol - tablet - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - clarithromycin - film coated tablet - 500 milligram

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 50 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol tablets are contraindicated in patients with: - heart failure of any severity: cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv heart failure. - hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) teratogenic effects pregnancy category c . cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventri

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 100 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol is contraindicated in patients with: - heart failure of any severity: cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv heart failure. - hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema). teratogenic effects pregnancy category c . cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular se

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 100 mg - cilostazol tablets, usp are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol is contraindicated in patients with: teratogenic effects pregnancy category c. cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic arch and subclavian artery abnormalities, renal pelvic dilation, 14th   rib, and retarded ossification). at this dose, systemic exposure to unbound cilostazol in nonpregnant rats was about 5 times the exposure in humans given the mrhd. increased incidences of ventricular septal defect and retarded ossification were also noted at 150 mg/kg/d

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 50 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol tablets are contraindicated in patients with: teratogenic effects pregnancy category c . cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic arch and subclavian artery abnormalities, renal pelvic dilation, 14th rib, and retarded ossification). at this dose, systemic exposure to unbound cilostazol in nonpregnant rats was about 5 times the exposure in humans given the mrhd. increased incidences of ventricular septal defect and retarded ossification were also noted at 150 mg/kg/d

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 100 mg - cilostazol tablets usp are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv congestive heart failure. cilostazol is contraindicated in patients with congestive heart failure of any severity. cilostazol tablets are contraindicated in patients with hemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. cilostazol inhibits platelet aggregation in a reversible manner. cilostazol tablets are contraindicated in patients with known or suspected hypersensitivity to any of their components.

United States - English - NLM (National Library of Medicine)

cardinal health - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 100 mg - cilostazol is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv congestive heart failure. cilostazol is contraindicated in patients with congestive heart failure of any severity. cilostazol is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. cilostazol inhibits platelet aggregation in a reversible manner. cilostazol is contraindicated in patients with known or suspected hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 50 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol tablets are contraindicated in patients with: - heart failure of any severity: cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv heart failure. - hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) teratogenic effects cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic ar